SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person *

Geist William

(Last) (First) (Middle)

614 MCKINLEY PLACE NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol

BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction (Month/Day/Year)

08/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director | 10% Owner

X Officer (give title below) | Other (specify below)

PRESIDENT, PROTEIN SCIENCES

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								24,943	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	$100.39							(1)	02/01/2029	Common Stock	15,912		15,912	D	
Stock Options (Right to Buy)	$94.52							(1)	08/15/2029	Common Stock	29,600		29,600	D	
Stock Options (Right to Buy)	$84.61							(1)	08/15/2030	Common Stock	1,526		1,526	D	
Stock Options (Right to Buy)	$84.61							(2)	08/15/2030	Common Stock	30,059		30,059	D	
Stock Options (Right to Buy)	$74.91							(3)	08/15/2034	Common Stock	21,204		21,204	D	
Stock Options (Right to Buy)	$53.6							(4)	08/15/2035	Common Stock	24,758		24,758	D	
Performance Restricted Stock Units	(5)							(6)	(6)	Common Stock	15,738		15,738	D	
Performance Restricted Stock Units	(5)							(7)	(7)	Common Stock	19,355		19,355	D	
Restricted Stock Units	(5)							(8)	(8)	Common Stock	2,623		2,623	D	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(5)							(9)	(9)	Common Stock	3,226		6,452	D	
Restricted Stock Units	(5)	08/17/2026		A		14,762		(10)	(10)	Common Stock	14,762	$0	14,762	D	
Restricted Stock Units	(5)	08/17/2026		A		23,985		(11)	(11)	Common Stock	23,985	$0	23,985	D	

Explanation of Responses:

1. 100% vested.
2. Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
3. Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
4. Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028.
5. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
8. 2,623 restricted stock units vest on 8/15/2027.
9. 3,226 restricted stock units vest on each of 8/15/2027 and 8/15/2028.
10. 4,921 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 4,920 restricted stock units vest on 8/17/2029.
11. 23,985 restricted stock units vest on 8/17/2029.

/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed	08/19/2026
** Signature of Reporting Person	Date